Prolonging the Honeymoon Phase in Type 1 Diabetes

Type 1 diabetes  is a chronic autoimmune disease marked by progressive destruction of pancreatic β cells and lifelong dependence on insulin. The transient honeymoon phase, a period of partial remission with improved metabolic control and reduced insulin needs, offers a critical therapeutic window to preserve residual β-cell function. This review highlights emerging strategies to prolong the honeymoon phase and modify disease progression. The anti-CD3 monoclonal antibody Teplizumab, the first FDA-approved disease-modifying therapy for T1D, delays clinical onset and preserves C-peptide secretion. Complementary immunomodulators such as baricitinib, rituximab, golimumab, verapamil, anti-thymocyte globulin, and DPP-4 inhibitors target distinct immune and metabolic pathways. Lifestyle interventions as optimized diet, vitamin D supplementation, and regular exercise further enhance insulin sensitivity and β-cell survival. Integrating these approaches through combination and personalized therapies may counteract immune dysregulation, oxidative stress, and viral triggers that accelerate β-cell loss. Collectively, these advances signal a paradigm shift from reactive insulin replacement toward proactive disease modification, offering renewed hope for extending remission and improving long-term outcomes in individuals with T1D.